Alpha Tau Reports Increased Net Loss for 2025, Bolstered by Strong Cash Position and Significant Clinical & Regulatory Progress
DRTS has more than doubled off its 52-week low of $2.3.
Summary
Alpha Tau Medical reported a larger net loss for 2025 but significantly increased its cash reserves, while also detailing substantial progress in clinical trials, regulatory submissions, and manufacturing for its Alpha DaRT® cancer therapy.
Key Events · Earnings and Guidance · DRTS
-
Increased Net Loss for 2025
The company reported a net loss of $42.6 million for the full year 2025, an increase from $31.8 million in 2024, primarily due to higher R&D and G&A expenses as clinical activities expanded.
-
Strengthened Cash Position
Cash, cash equivalents, and deposits increased to $76.9 million as of December 31, 2025, up from $62.9 million at the end of 2024, providing a robust financial runway for ongoing operations.
-
Significant Clinical Pipeline Progress
Alpha Tau received FDA approval to initiate a pilot study for prostate cancer, treated its first patient in a recurrent glioblastoma multiforme (GBM) trial, and presented positive data from its pancreatic cancer study at ASCO GI Symposium.
-
Advancements in Regulatory Submissions
The first module of the pre-market approval (PMA) application for recurrent cutaneous squamous cell carcinoma (cSCC) was submitted to the U.S. FDA, marking a key step towards U.S. marketing authorization.
Analysis · DRTS · Industrial Applications And Services
Alpha Tau Medical reported an increased net loss for the full year 2025, which is typical for a clinical-stage biotechnology company. However, this was accompanied by a substantial increase in cash and equivalents, providing a strengthened balance sheet and extended operational runway. The corporate update highlighted significant advancements in its Alpha DaRT® therapy pipeline, including new clinical trial approvals, initiation of patient treatments, positive data presentations, and progress towards U.S. marketing authorization. These operational and regulatory milestones, coupled with a solid cash position, are critical for a development-stage company and outweigh the increased net loss, indicating strong execution on its strategic goals.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DRTS was trading at $6.54 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $572.1M. The 52-week trading range was $2.30 to $8.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.